Since their introduction in 2005, GLP-1 medications like Ozempic and Wegovy have transformed diabetes treatment and weight management. Our new report highlights the impact of GLP-1 use on consumer spending habits, particularly on food, beverages, and non-food products. It also highlights the opportunity for CPG companies to help consumers on their weight loss journeys through product innovation, educational campaigns, personalized meal planning, partnerships with health care providers, and more. 

Highlights:

• On average, households with GLP-1 weight loss users typically spend more than nonuser households on CPG food, beverages, and foodservice before they even initiate use of a GLP-1.

• Sales of gastrointestinal products increased among GLP-1 users seeking relief from the medication’s side effects. The data also shows during the first year of usage, consumers decreased spending on sleep remedies, analgesics, and home health care products as overall health improved.

• The biggest shift in grocery spending was in frozen foods, where GLP-1 weight loss users’ monthly spending fell three points from their pre-usage baseline during their first year on the drug.

• GLP-1 weight loss users initially skew their spending toward quick-serve restaurants.

  
  

Register for the free webinar: The Ripple Effect of GLP-1s, Today and in the Future on January 8, 2025, at 1:00 p.m. PM CT.

---

Circana's Insights on GLP-1s and How They Impact Spending

Circana has been tracking the growth and evolution of GLP-1s and their relative impact on purchase decisions amidst this unique consumer segment.

View Circana's GLP-1 Shoppers Insight Collection

You can also learn more how to drive growth among these users through Circana’s GLP-1 Activation Playbook.